LegoChem Biosciences (Korea) Performance
| 141080 Stock | KRW 95,800 400.00 0.42% |
The company secures a Beta (Market Risk) of -0.3, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning LegoChem Biosciences are expected to decrease at a much lower rate. During the bear market, LegoChem Biosciences is likely to outperform the market. At this point, LegoChem Biosciences has a negative expected return of -0.32%. Please make sure to verify LegoChem Biosciences' market risk adjusted performance, semi deviation, coefficient of variation, as well as the relationship between the mean deviation and downside deviation , to decide if LegoChem Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days LegoChem Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in May 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Total Cashflows From Investing Activities | -43.9 B |
LegoChem |
LegoChem Biosciences Relative Risk vs. Return Landscape
If you would invest 11,920,000 in LegoChem Biosciences on January 4, 2025 and sell it today you would lose (2,300,000) from holding LegoChem Biosciences or give up 19.3% of portfolio value over 90 days. LegoChem Biosciences is generating negative expected returns and assumes 2.8957% volatility on return distribution over the 90 days horizon. Simply put, 25% of stocks are less volatile than LegoChem, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
LegoChem Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for LegoChem Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as LegoChem Biosciences, and traders can use it to determine the average amount a LegoChem Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1089
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 141080 |
Estimated Market Risk
| 2.9 actual daily | 25 75% of assets are more volatile |
Expected Return
| -0.32 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average LegoChem Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of LegoChem Biosciences by adding LegoChem Biosciences to a well-diversified portfolio.
LegoChem Biosciences Fundamentals Growth
LegoChem Stock prices reflect investors' perceptions of the future prospects and financial health of LegoChem Biosciences, and LegoChem Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on LegoChem Stock performance.
| Return On Equity | -2.16 | |||
| Return On Asset | 0.04 | |||
| Profit Margin | 0.24 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 1.09 T | |||
| Shares Outstanding | 10.6 M | |||
| Price To Sales | 9.51 X | |||
| Revenue | 32.16 B | |||
| EBITDA | 12.28 B | |||
| Cash And Equivalents | 29.39 B | |||
| Total Debt | 9.41 B | |||
| Debt To Equity | 0.40 % | |||
| Cash Flow From Operations | (42.05 B) | |||
| Total Asset | 293.23 B | |||
| Retained Earnings | (38.4 B) | |||
| Current Asset | 29.6 B | |||
| Current Liabilities | 11.13 B | |||
About LegoChem Biosciences Performance
By analyzing LegoChem Biosciences' fundamental ratios, stakeholders can gain valuable insights into LegoChem Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if LegoChem Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if LegoChem Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
LegoChem Biosciences, Inc. a biopharmaceutical company, focuses on the development of novel therapeutics utilizing its proprietary LegoChemistry medicinal drug discovery technology and ADC platform. LegoChem Biosciences, Inc. was founded in 2006 and is headquartered in Daejeon, South Korea. LegoChem Bio is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about LegoChem Biosciences performance evaluation
Checking the ongoing alerts about LegoChem Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for LegoChem Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| LegoChem Biosciences generated a negative expected return over the last 90 days | |
| The company reported the revenue of 32.16 B. Net Loss for the year was (23.39 B) with profit before overhead, payroll, taxes, and interest of 34.81 B. | |
| LegoChem Biosciences has accumulated about 29.39 B in cash with (42.05 B) of positive cash flow from operations. | |
| Roughly 20.0% of the company shares are owned by insiders or employees |
- Analyzing LegoChem Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether LegoChem Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining LegoChem Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating LegoChem Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of LegoChem Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of LegoChem Biosciences' stock. These opinions can provide insight into LegoChem Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for LegoChem Stock analysis
When running LegoChem Biosciences' price analysis, check to measure LegoChem Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LegoChem Biosciences is operating at the current time. Most of LegoChem Biosciences' value examination focuses on studying past and present price action to predict the probability of LegoChem Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LegoChem Biosciences' price. Additionally, you may evaluate how the addition of LegoChem Biosciences to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |